By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Immunitor 



Vancouver  British Columbia    Canada
Phone: 360-566-2194 Fax: n/a


SEARCH JOBS

Immunitor Inc. is a privately held, Vancouver headquartered commercial stage biopharmaceutical company (www.immunitor.com) with offices in Beijing, Johannesburg, Moscow and Ulaanbaatar. Immunitor's strength resides in its proprietary oral vaccine platform validated by numerous clinical trials conducted over the past 15 years. Immunitor makes several immunotherapy products addressing major health problems, i.e., in infectious diseases area: HIV, HBV, HCV, influenza, malaria, fungal and microbial infections including tuberculosis; in the area of autoimmune and metabolic diseases: i.e., allergy, renal failure, thyroiditis, Alzheimer disease, hypertension, atherosclerosis, obesity and diabetes; and recently in oncology space, with several candidates currently being investigated. They are all based on clinically proven rationale that regulation of disease-associated inflammation produces therapeutic benefit.

YEAR FOUNDED:

2000

LEADERSHIP:

CEO: Aldar S. Bourinbaiar

PRODUCTS:

All Products

FOLLOW IMMUNITOR:



Key Statistics


Email: info@immunitor.com
Ownership: Subsidiary

Web Site: Immunitor
Employees:
Symbol: 
 



Industry
Biotechnology

Segment
Vaccines





Company News
Immunitor Release: Key Capital Announces Terminal Liver Cancer Trial Results Publication 4/13/2017 11:58:33 AM
Immunitor Release: Key Capital Corporation Announces Immunotherapy Product Rights Agreement 3/7/2017 9:23:30 AM
Immunitor's Breakthrough In Cancer Immunotherapy 6/25/2014 8:11:11 AM
Immunitor USA Inc. CEO Joins Immune Network Ltd. (IMMFF) Board of Directors 2/14/2011 10:21:21 AM
Immunitor USA Inc. Publishes Interim Data From Phase IIB Imm01 TB Trial 12/30/2010 6:45:01 AM
Immunitor USA Inc.r Completes Business Trip to China and Presents at Chinese Academy of Science Annual TB Meeting 12/13/2010 11:37:07 AM
Immunitor USA Inc. Awarded the Key U.S. Patent Related to Oral Vaccine Technology Platform 11/29/2010 9:23:14 AM
Immunitor USA Inc.'s V5 Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week 11/1/2010 11:47:55 AM
Immunitor USA Inc. Release: Bird Flu Oral Vaccine Licensed By MDM Group 3/14/2006 1:22:12 PM
//-->